Zevra Therapeutics (ZVRA) Equity Ratio (2014 - 2026)

Zevra Therapeutics has reported Equity Ratio for 13 years, with the latest figure at 0.74 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 211.02% year-over-year to 0.74; the trailing twelve-month figure through Mar 2026 stood at 0.74 (up 211.02% YoY), and the FY2025 full-year result was 0.54, up 143.92% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.74, up from 0.54 in the prior quarter.
• The five-year high for Equity Ratio was 3.45 in Q1 2022, with the low at 0.22 in Q4 2024.
• Historically, Equity Ratio has averaged 0.66 across 5 years, with a median of 0.46 in 2025.
• Annual changes were most pronounced in 2022 — Equity Ratio jumped 270.48% — and 2023, when it plunged 83.89%.
• Zevra Therapeutics' Equity Ratio stood at 0.65 in 2022, then plunged by 44.88% to 0.36 in 2023, then slumped by 37.97% to 0.22 in 2024, then jumped by 143.92% to 0.54 in 2025, then soared by 36.01% to 0.74 in 2026.
• The last three Equity Ratio figures came in at 0.74 (Q1 2026), 0.54 (Q4 2025), and 0.49 (Q3 2025), per Business Quant data.